Nancy Pelosi's AI Pick Set for Gains After Price Target Update
Tempus AI has gained 162% this year and has potential for further gains.
You're reading 0 of 1 free page.
Register to read more or Unlock Pro — 50% Off Ends Soon
“Get well soon,” we say to someone who is under the weather. Meanwhile, AI is doing more in the medical field than simply wishing patients well.
X-rays, MRIs and CT scans can now be analyzed by AI algorithms. These algos can analyze huge amounts of data quickly, and can even diagnose patients and recommend treatments. In this way, AI frees medical professionals to provide their critical services with greater efficiency.
Tempus AI Takes Off
I mention this because shares of Tempus AI TEM roared to a 13% gain on Thursday, after the Chicago-based healthcare company received FDA approval for an AI-focused cardiac imaging device.
A company official said the Tempus Pixel will allow, “...a comprehensive view of heart tissue, enabling deeper insights into cardiac health.”
When we recommended Tempus AI in June, we placed the target at $90 and warned that “it could happen fast.” That target was reached on Thursday, representing a gain of about 33% in just three months. Tempus AI has now gained 160% year-to-date.
Shares of Tempus AI reached that $90 price target, which was based on a previous area of resistance (black dotted line). The stock closed just below its all-time high on Thursday.
Tempus AI Is a Nancy Pelosi Pick
One investor who must be pleased with her investment in Tempus AI is former U.S. House of Representatives Speaker Nancy Pelosi. Pelosi purchased Tempus AI calls in January, with a strike price of $20. Pelosi’s purchase was made on January 14, when the stock was trading in the low $30s.
The calls are set to expire in January 2026. Some investors copy Pelosi's picks, due to her winning track record.
Tempus AI Looks to the Future
Imagine a healthcare professional that is an expert in all fields of medicine, and is available to you 24/7. There is no need for an appointment, because this cloud-based professional is always on call.
In the long run, that could be where AI-enhanced healthcare is headed. Tempus is one of the leading names in this sector right now, and with a market capitalization of $15 billion, the stock still has plenty of room to grow.
At the time of publication, Ponsi was long TEM.
